Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:
“ESMO Breast 2025
Great Debate on Continuing CDK4/6 After Progression!
Kevin Kalinsky: Yes, switching ET with CDK4/6i improves PFS (e.g., imunestrant+abemaciclib 9.1 mo). Reasonable option.
Fabrice Andre: No, no meaningful clinical benefit, abemaciclib modest, CDK4/6i not ideal for optimal combos.
What do you think?”
More posts featuring ESMO Breast 2025.
